N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 163, P. 114846 - 114846

Published: May 9, 2023

The emergence of drug resistance and metastasis has long been a difficult problem for cancer treatment. Recent studies have shown that stem cell populations are key factors in the regulation aggressiveness, relapse resistance. Cancer (CSC) highly plastic self-renewing, giving them unique metabolic, metastatic, chemotherapy properties. N6-methyladenosine (m6A) is most abundant internal modification mRNA involved variety growth development processes, including RNA transcription, alternative splicing, degradation, translation. It also linked to various cancers. At present, important role m6A tumour progression gradually attracting attention, especially stemness process. Abnormal modifications regulate metastasis, recurrence This paper aims explore regulatory mechanism CSCs clinical therapy, clarify its network, provide theoretical guidance targets improvement therapeutic effects.

Language: Английский

---

PD-L1 at the crossroad between RNA metabolism and immunosuppression

Trends in Molecular Medicine, Journal Year: 2024, Volume and Issue: 30(7), P. 620 - 632

Published: May 31, 2024

Language: Английский

---

Hydroxychloroquine Platinum(IV) Conjugate Displaying Potent Antimetastatic Activities by Suppressing Autophagy to Improve the Tumor Microenvironment

Dalton Transactions, Journal Year: 2024, Volume and Issue: 53(33), P. 13890 - 13905

Published: Jan. 1, 2024

Protective autophagy is a promising target for antitumor drug exploration. A hydroxychloroquine (HCQ) platinum(IV) complex with suppressing potency was developed, which displayed potent activities TGI rate of 44.2% against 4T1 tumors

Language: Английский

---

The YTH domain‐containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(8)

Published: Aug. 1, 2024

The modification of N6-methyladenosine (m6A) plays a pivotal role in tumor by altering both innate and adaptive immune systems through various pathways, including the regulation messenger RNA. YTH domain protein family, acting as "readers" m6A modifications, affects RNA splicing, stability, immunogenicity, thereby playing essential roles antitumor immunity. Despite their significance, impact family on initiation progression, well involvement therapy, remains underexplored lacks comprehensive review.

Language: Английский

---

Non-canonical translation in cancer: significance and therapeutic potential of non-canonical ORFs, m6A-modification, and circular RNAs

Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)

Published: Sept. 27, 2024

Language: Английский

---

APOM Modulates the Glycolysis Process in Liver Cancer Cells by Controlling the Expression and Activity of HK2 via the Notch Pathway

Biochemical Genetics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

Language: Английский

---

New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 22, 2025

N6-methylation is a modification in which methyl group added to the adenine base of nucleotide. This crucial for controlling important functions that are vital gene expression, including mRNA splicing, stability, and translation. Due its intricate participation both normal cellular processes course disease, as well critical role determining cell fate, N6-methyladenosine (m 6 A) alteration has recently attracted lot interest. The formation progression many diseases, especially cancer, can be attributed dysregulated m A alteration, cause disturbances variety functions, such immunological responses, proliferation, differentiation. In this study, we examine how dysregulation affects hepatocellular carcinoma (HCC), with particular emphasis on it contributes evasion carcinogenesis. We also investigate potential novel therapeutic target, providing new perspectives approaches meant enhance clinical results patients HCC.

Language: Английский

---

“Friends or foes”: a new perspective of tumour metabolic transcriptional modification

Cell Death and Disease, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 17, 2025

Abstract Energy metabolism plays a pivotal role in cancer clinical treatment and has become an important means of diagnosis tumour progression. However, current research mostly focuses on changes metabolic products neglects the deeper mechanisms transcriptional regulation. This paper proposes new perspective, establishing comprehensive network that reveals interaction between transcription, which explores how affects progression through modifications, provides novel approach for optimizing strategies. viewpoint is conducive to overcoming bottlenecks promoting development drug combinations personalized medicine.

Language: Английский

---

Pharmacology of Epitranscriptomic Modifications: Decoding the Therapeutic Potential of RNA Modifications in Drug Resistance

European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: 994, P. 177397 - 177397

Published: Feb. 18, 2025

Language: Английский

---

The biological roles and molecular mechanisms of m6A reader IGF2BP1 in the hallmarks of cancer

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101567 - 101567

Published: Feb. 1, 2025

Language: Английский

---